Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Zymeworks Inc (NY: ZYME )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
Chinese Growth Level
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
Europe's Unicorns
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
Markets Boosted
Good news helped stock prices. 
Via Talk Markets
Perfumes Of Arabia
Downtrends do eventually run out of pessimistic steam, but it can take a while. 
Via Talk Markets
Sweet Smell Of Recovery
Markets today saw many reversals of moves by ADR companies in the course of the day, mainly because of macro changes. 
Via Talk Markets
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
From Zymeworks Inc.
Via Business Wire
October Starts Positive
A lot of these moves are simply reactions to last month's excesses and they may not be predictive for October at all. 
Via Talk Markets
Multiple Bits Of Bad News
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser. 
Via Talk Markets
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
From Zymeworks Inc.
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
From Zymeworks Inc.
Via Business Wire
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
The Real World
The rise of the delta has caused markets to drop back after the rises earlier although inflation still remains within a point or two of forecasts at 5.3-5.4% annualized. 
Via Talk Markets
Delta Outbreak
The US market was droopy because of poor private sector jobless numbers. 
Via Talk Markets
Zymeworks Reports 2021 Second Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
Markets: COVID Is Back
BP Plc reported earnings beats of 22 cents with a Q2 eps of 83 cents. Schlumberger Ltd, normally supported by French descendants from the founding Alsatian brothers, was hit by concern about the price... 
Via Talk Markets
Topics Earnings
Exposures Financial
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
From Zymeworks Inc.
Via Business Wire
Banned Merger
Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood. 
Via Talk Markets
Chinese Stock Crash
For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on... 
Via Talk Markets
Delta Defeats Bulls
Stocks tended to crash without rhyme or reason. 
Via Talk Markets
Weak Week
Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism. 
Via Talk Markets
Powell Talks Some More
Another day, another sell-off. 
Via Talk Markets
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Fireworks Display
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked. 
Via Talk Markets
People Needed
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
Exposures Labor
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.